These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6296300)

  • 1. Alterations in coxsackievirus B4 heart muscle disease in ICR Swiss mice by anti-thymocyte serum.
    Khatib R; Khatib G; Chason JL; Lerner AM
    J Gen Virol; 1983 Jan; 64 (Pt 1)():231-6. PubMed ID: 6296300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of pre-existing coxsackievirus B4 myocardial disease on the expression of coxsackievirus B3 myocarditis.
    Khatib R; Reyes MP; Khatib G; Giraldo A
    Can J Cardiol; 1993 Jun; 9(5):444-7. PubMed ID: 8394194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited persistence of viral antigen in coxsackievirus B3 induced heart disease in mice.
    Roesing TG; Landau BJ; Crowell RL
    Proc Soc Exp Biol Med; 1979 Mar; 160(3):382-6. PubMed ID: 219431
    [No Abstract]   [Full Text] [Related]  

  • 4. Differential recruitment of B and T cells in coxsackievirus B4-induced pancreatitis is influenced by a capsid protein.
    Ramsingh AI; Lee WT; Collins DN; Armstrong LE
    J Virol; 1997 Nov; 71(11):8690-7. PubMed ID: 9343227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease.
    Woodruff JF; Woodruff JJ
    J Immunol; 1974 Dec; 113(6):1726-34. PubMed ID: 4610045
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of subsequent myocardial damage on the expression of coxsackievirus B4 myocarditis and the development of ventricular aneurysms.
    Khatib R; Khatib G; Reyes MP; Giraldo A
    Eur Heart J; 1994 Aug; 15(8):1140-3. PubMed ID: 7988609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental coxackievirus B 1 infection in immunologically altered mice.
    Petrovicová A
    J Hyg Epidemiol Microbiol Immunol; 1983; 27(2):149-54. PubMed ID: 6309957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of cytotoxic T lymphocytes during coxsackievirus B-3 infection. III. Role of sex.
    Wong CY; Woodruff JJ; Woodruff JF
    J Immunol; 1977 Aug; 119(2):591-7. PubMed ID: 301899
    [No Abstract]   [Full Text] [Related]  

  • 9. Coxsackievirus infection of mice. II. Viral kinetics and histopathological changes in mice experimentally infected with coxsackievirus B3 by intraperitoneal route.
    Vargová A; Bopegamage S; Borsanyiová M; Petrovicová A; Benkovicová M
    Acta Virol; 2003; 47(4):253-7. PubMed ID: 15068381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coxsackievirus B 1-induced polymyositis. Lack of disease expression in nu/nu mice.
    Ytterberg SR; Mahowald ML; Messner RP
    J Clin Invest; 1987 Aug; 80(2):499-506. PubMed ID: 3038960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coxsackievirus B3-induced myocarditis in MHC class II-deficient mice.
    Leipner C; Borchers M; Merkle I; Stelzner A
    J Hum Virol; 1999; 2(2):102-14. PubMed ID: 10225212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A point mutation in VP1 of coxsackievirus B4 alters antigenicity.
    Halim S; Ramsingh AI
    Virology; 2000 Mar; 269(1):86-94. PubMed ID: 10725201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-coxsackievirus B4 (CV-B4) enhancing activity of serum associated with increased viral load and pathology in mice reinfected with CV-B4.
    Elmastour F; Jaïdane H; Benkahla M; Aguech-Oueslati L; Sane F; Halouani A; Engelmann I; Bertin A; Mokni M; Gharbi J; Aouni M; Alidjinou EK; Hober D
    Virulence; 2017 Aug; 8(6):908-923. PubMed ID: 27792461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic predisposition to diabetes mellitus is associated with impaired humoral immunity to coxsackievirus B4.
    Loria RM; Montgomery LB; Tuttle-Fuller N; Gregg HM; Chinchilli VM
    Diabetes Res Clin Pract; 1986 May; 2(2):91-6. PubMed ID: 3013555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis.
    Hiraoka Y; Kishimoto C; Kurokawa M; Ochiai H; Sasayama S
    J Pharmacol Exp Ther; 1992 Mar; 260(3):1386-91. PubMed ID: 1372051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coxsackievirus infection of mice. I. Viral kinetics and histopathological changes in mice experimentally infected with coxsackieviruses B3 and B4 by oral route.
    Bopegamage S; Borsanyiová M; Vargová A; Petrovicová A; Benkovicová M; Gomolcák P
    Acta Virol; 2003; 47(4):245-51. PubMed ID: 15068380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of cytotoxic T lymphocytes during coxsackievirus B-3 infection. I. Model and viral specificity1.
    Wong CY; Woodruff JJ; Woodruff JF
    J Immunol; 1977 Apr; 118(4):1159-64. PubMed ID: 300399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of exercise-aggravated coxsackievirus B3 murine myocarditis by T lymphocyte suppression in an inbred model.
    Cabinian AE; Kiel RJ; Smith F; Ho KL; Khatib R; Reyes MP
    J Lab Clin Med; 1990 Apr; 115(4):454-62. PubMed ID: 2157783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury.
    Chow LH; Beisel KW; McManus BM
    Lab Invest; 1992 Jan; 66(1):24-31. PubMed ID: 1309927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of coxsackievirus B4 virulence by indomethacin.
    Khatib R; Reyes MP; Smith F; Khatib G; Rezkalla S
    J Lab Clin Med; 1990 Jul; 116(1):116-20. PubMed ID: 1695914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.